Skip to main content
Clinical Trials/KCT0008111
KCT0008111
Completed
未知

ong-term clinical outcome of chronic hepatitis B naive patients treated with entecavir and tenofovir in Korea

Hallym University Medical Center-Dongtan0 sites2,000 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Certain infectious and parasitic diseases
Sponsor
Hallym University Medical Center-Dongtan
Enrollment
2000
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
June 15, 2022
Last Updated
3 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Hallym University Medical Center-Dongtan

Eligibility Criteria

Inclusion Criteria

  • Patients who were prescribed entecavir as an initial treatment for chronic hepatitis B between January 2011 and January 2014
  • Patients who were prescribed tenofovir as an initial treatment for chronic hepatitis B between December 2012 and December 2015

Exclusion Criteria

  • Patients who could not be followed up within 1 year after administration of entecavir or tenofovir
  • Patients diagnosed with liver cancer before and within 1 year after administration of entecavir or tenofovir
  • Patients diagnosed with other types of malignancies during the 5 years prior to administration of entecavir or tenofovir
  • Patients co\-infected with HCV or HIV

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)Chronic hepatitis B
JPRN-UMIN000031832Stanford University Medical Center270
Recruiting
Not Applicable
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate PhaseChronic Hepatitis b
NCT05661786The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School4,500
Active, not recruiting
Not Applicable
A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir PlusTenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides: The BE-LOW Study.Revised Protocol 01, incorporating protocol amendment 02 (Version 2.0, Date 22-Jan-07). - The BE-LOW Study
EUCTR2006-000421-62-GRBristol-Myers Squibb International Corporation462
Active, not recruiting
Not Applicable
A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides: The BE-LOW Study - The BE-LOW StudyCHRONIC HEPATITIS B VIRUS,TREATMENT-NAIVMedDRA version: 6.1Level: PTClassification code 10019731
EUCTR2006-000421-62-ITBristol-Myers Squibb International Corporation462
Active, not recruiting
Phase 1
A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir PlusTenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides: The BE-LOW Study.Revised Protocol 01, incorporating protocol amendment 02 (Version 2.0, Date 22-Jan-07). - The BE-LOW StudyCHRONIC HEPATITIS B VIRUS,TREATMENT-NAIVMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)
EUCTR2006-000421-62-FRBristol-Myers Squibb International Corporation462